Form 4: Nurix Director Exercises Stock Options

Sentiment:

Insider Transaction Report


Julia P. Gregory, a Director at Nurix Therapeutics, Inc., exercised options to acquire 10,750 shares of common stock at $1.86 per share.

Summary

  • Julia P. Gregory, a Director of Nurix Therapeutics, Inc. (NRIX), exercised stock options to acquire common stock.
  • On September 17, 2025, Ms. Gregory acquired 10,750 shares of common stock at an exercise price of $1.86 per share.
  • Following this transaction, Ms. Gregory directly owns 10,750 shares of common stock.
  • She also beneficially owns 22,583 derivative securities (stock options).
  • The exercised stock option vested monthly starting September 12, 2019, and was fully vested on August 12, 2023.

Sentiment

Score: 6

Explanation: The exercise of stock options by a director is generally a neutral to slightly positive event, indicating continued engagement and a potential belief in the company's future, but it's a routine compensation event rather than a significant strategic move.

Positives

  • An insider, Julia P. Gregory, is increasing her direct ownership in the company by exercising stock options, which can be seen as a sign of confidence in the company's future prospects.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

  • Julia P. Gregory, a Director of Nurix Therapeutics, Inc., engaged in a transaction involving the company's securities, which constitutes a related party transaction.

Stakeholder Impact

  • Shareholders: The transaction increases a director's direct ownership, potentially aligning her interests more closely with shareholders.
  • Employees: No direct impact on employees is indicated.
  • Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated.

Key Dates

DateDescription
09/12/2019Start date for monthly vesting of the stock option.
08/12/2023Date when the stock option was fully vested.
09/17/2025Date of the stock option exercise and acquisition of common stock.
12/22/2029Expiration date of the Director Stock Option.

Keywords

Nurix Therapeutics, NRIX, Julia P. Gregory, Stock Option Exercise, Insider Transaction, Form 4, Director Stock Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.